Melatonin is a methoxyindole synthesized and secreted principally by the pineal gland at night under normal environmental conditions. The endogenous rhythm of secretion is generated by the suprachiasmatic nuclei and entrained to the light/dark cycle. Light is able to either suppress or synchronize melatonin production according to the light schedule. The nycthohemeral rhythm of this hormone can be determined by repeated measurement of plasma or saliva melatonin or urine sulfatoxymelatonin, the main hepatic metabolite. The primary physiological function of melatonin, whose secretion adjusts to night length, is to convey information concerning the daily cycle of light and darkness to body physiology. This information is used for the organisation of functions, which respond to changes in the photoperiod such as the seasonal rhythms. Seasonal rhythmicity of physiological functions in humans related to possible alteration of the melatonin message remains, however, of limited evidence in temperate areas in field conditions. Also, the daily melatonin secretion, which is a very robust biochemical signal of night, can be used for the organisation of circadian rhythms. Although functions of this hormone in humans are mainly based on correlative observations, there is some evidence that melatonin stabilises and strengthens coupling of circadian rhythms, especially of core temperature and sleep-wake rhythms. The circadian organisation of other physiological functions could depend on the melatonin signal, for instance immune, antioxidative defences, hemostasis and glucose regulation. Since the regulating system of melatonin secretion is complex, following central and autonomic pathways, there are many pathophysiological situations where the melatonin secretion can be disturbed. The resulting alteration could increase predisposition to disease, add to the severity of symptoms or modify the course and outcome of the disorder.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.smrv.2004.08.001 | DOI Listing |
Vet Res Commun
January 2025
Laboratory of Veterinary Physiology, Department of Veterinary Medicine, Faculty of Agriculture, Tokyo University of Agriculture and Technology, 3-5-8 Saiwai-Cho, 183-8509, Fuchu, Tokyo, Japan.
This study investigated, for the first time, the alterations in the uterine echotexture and blood flow in cyclic and acyclic (inactive ovary) goats using ultrasonography. The study aimed also to evaluate the metabolomic changes in the plasma of cyclic and acyclic goats. Furthermore, the histopathological approach was applied to the specimens of the uterus to validate the findings of this study.
View Article and Find Full Text PDFBackground: Individuals with Alzheimer's disease often exhibit white matter microstructure degenerations observable through diffusion tensor imaging (DTI). The circadian system regulates sleep and wake cycles. As people age, sleep and wake cycles can be disrupted, which can worsen sleep quality.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
UK Dementia Research Institute, Care Research and Technology Centre, Imperial College London and the University of Surrey, Guildford, UK.
Background: Disruption in diurnal rest-activity rhythms is a hallmark of Alzheimer's disease. Currently, we know little about how physiology, symptoms, and biomarkers change over the 24-hour day in people living with Alzheimer's disease. In particular, we don't know whether plasma biomarkers of neurodegeneration, which offer promise as diagnostic or stratification tools, vary with time of day, and whether these associate with the circadian markers melatonin and cortisol.
View Article and Find Full Text PDFBackground: About half of the patients suffering from Alzheimer's disease (AD) display sleeping disorders. Disruptions in the central circadian clock (CC), located in the brain, accelerate AD pathogenesis, making the CC a promising target. In preclinical trials, this strategy have shown efficacy but clinical results are inconsistent.
View Article and Find Full Text PDFBackground: This study investigates the impact of IGC-AD1, a combination comprising of low concentration of delta-9 tetrahydrocannabinol ("THC") and melatonin on blood serum potassium levels in patients with Alzheimer's disease ("AD"). Loss of intracellular compartmentalization of potassium is a characteristic of AD pathology, with supporting studies indicating significantly lower potassium levels in intracellular compartments of AD brains and an associated increase in serum potassium levels in AD subjects. Here, we present preliminary safety lab data from a Phase I trial of AD patients administered with IGC-AD1.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!